Study aims to pinpoint ideal imatinib dose for GIST patients

NCT ID NCT07614841

Completed Knowledge-focused Sponsor: First Affiliated Hospital, Sun Yat-Sen University Source: ClinicalTrials.gov ↗

First seen Jun 05, 2026 · Last updated Jun 20, 2026 · Updated 4 times

Summary

This completed study looked at 328 patients with intermediate or high-risk gastrointestinal stromal tumors (GIST) who took imatinib after surgery. The goal was to find the best dose that balances effectiveness and side effects. Researchers measured drug levels in the blood and tracked tumor recurrence or death.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

imatinib

What this could lead to

If successful, this could help doctors find the safest and most effective dose of imatinib for GIST patients after surgery.

What could go wrong

This is an observational study, not a controlled trial, so results may not prove cause and effect. The findings may not apply to all patients.

Conditions

The condition(s) this trial relates to.

gastrointestinal stromal tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROINTESTINAL STROMAL TUMORS (GISTS)